Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EBIT (2020 - 2025)

Historic EBIT for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$37.1 million.

  • TScan Therapeutics' EBIT fell 1357.98% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.7 million, marking a year-over-year decrease of 2444.29%. This contributed to the annual value of -$134.8 million for FY2024, which is 4425.84% down from last year.
  • Latest data reveals that TScan Therapeutics reported EBIT of -$37.1 million as of Q3 2025, which was down 1357.98% from -$38.7 million recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' EBIT peaked at -$7.9 million during Q1 2021, and registered a low of -$38.7 million during Q2 2025.
  • Over the past 5 years, TScan Therapeutics' median EBIT value was -$22.7 million (recorded in 2023), while the average stood at -$24.0 million.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 12091.76% in 2021, then plummeted by 464.59% in 2022.
  • Quarter analysis of 5 years shows TScan Therapeutics' EBIT stood at -$14.2 million in 2021, then crashed by 31.31% to -$18.6 million in 2022, then dropped by 14.52% to -$21.4 million in 2023, then crashed by 71.9% to -$36.7 million in 2024, then dropped by 0.93% to -$37.1 million in 2025.
  • Its EBIT stands at -$37.1 million for Q3 2025, versus -$38.7 million for Q2 2025 and -$36.2 million for Q1 2025.